Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China

Zai Lab Ltd

2022-Q2 EPS reported -$0.23 revenue$94,900,000

Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.
Cash position $1.26B; NMPA accepted BLA for efgartigimod in generalized myasthenia gravis.
Karuna's KarXT Phase 3 EMERGENT-2 met primary endpoint: 9.6-point PANSS reduction vs placebo (p<0.0001).
Josh Smiley appointed COO effective Aug 1; John Diekman named Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.